TriangleSacituzumab govitecan (NCT06263543)
Sacituzumab govitecan trial for Breast Cancer (NCT06263543). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with endocrine-refractory, hormone-receptor-positive, HER2-low or ultralow advanced unresectable or metastatic breast cancer. Prior CDK4/6 treatment and trastuzumab deruxtecan are required, with one to four prior metastatic chemotherapy regimens.
The idea: sacituzumab govitecan delivers a DNA-damaging payload to TROP2-bearing cells. Researchers test tumor response after earlier trastuzumab deruxtecan. Sacituzumab infusions occur on days one and eight of each three-week cycle, until progression or unacceptable toxicity. Prior trastuzumab deruxtecan may have stopped for progression or intolerance.
This phase 2 study plans 75 patients. Reshma Mahtani leads; three US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.